Literature DB >> 26459988

Induced pluripotent stem cells as a discovery tool for Alzheimer׳s disease.

Sarah E Sullivan1, Tracy L Young-Pearse2.   

Abstract

The ability to accurately and systematically evaluate the cellular mechanisms underlying human neurodegenerative disorders such as Alzheimer׳s disease (AD) should lead to advancements in therapeutics. Recent developments in human induced pluripotent stem cells (iPSCs) have afforded the opportunity to use human neurons and glia to study cellular changes involved in neurological diseases. iPSCs have the potential to be differentiated into AD-relevant cell types, including forebrain neurons, astrocytes, and microglia. This permits the evaluation of individual cell types in isolation or in concert, thus modeling the interdependence of cell types within the brain. When discussing the potential of modeling AD with iPSCs, it is important to remember that the umbrella diagnosis of "Alzheimer׳s disease" represents a disease that is heterogeneous in terms of age of onset, underlying causes, and at times precise pathology. The ability of iPSCs to be derived from an array of AD patients allows for a closer examination of the mechanism of disease progression in particular subsets of subjects, who may have different mutations and allelic variants affecting their risk for disease. Disease mechanisms can be probed both by the genetic manipulation of iPSCs and by modifications to the cellular environment by chemical treatment. These studies may lead not only to the refinement of known pathways implicated in AD, but also to the identification of novel pathways heretofore unaffiliated with disease pathology. In this review, we describe the potential of iPSC models to transform our understanding of AD and to lead to valuable advancements in therapeutics. This article is part of a Special Issue entitled SI: Exploiting human neurons.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer׳s disease; Aβ; Induced pluripotent stem cell; Stem cell; Tau; iPS

Mesh:

Year:  2015        PMID: 26459988      PMCID: PMC4833689          DOI: 10.1016/j.brainres.2015.10.005

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  62 in total

1.  Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome.

Authors:  Anne M Cataldo; Suzana Petanceska; Nicole B Terio; Corrinne M Peterhoff; Robert Durham; Marc Mercken; Pankaj D Mehta; Joseph Buxbaum; Vahram Haroutunian; Ralph A Nixon
Journal:  Neurobiol Aging       Date:  2004 Nov-Dec       Impact factor: 4.673

2.  Directed differentiation of functional astroglial subtypes from human pluripotent stem cells.

Authors:  Robert Krencik; Su-Chun Zhang
Journal:  Nat Protoc       Date:  2011-10-13       Impact factor: 13.491

3.  The specification of telencephalic glutamatergic neurons from human pluripotent stem cells.

Authors:  Erin M Boisvert; Kyle Denton; Ling Lei; Xue-Jun Li
Journal:  J Vis Exp       Date:  2013-04-14       Impact factor: 1.355

Review 4.  Structure, mechanism and inhibition of gamma-secretase and presenilin-like proteases.

Authors:  Michael S Wolfe
Journal:  Biol Chem       Date:  2010-08       Impact factor: 3.915

5.  Modeling familial Alzheimer's disease with induced pluripotent stem cells.

Authors:  Takuya Yagi; Daisuke Ito; Yohei Okada; Wado Akamatsu; Yoshihiro Nihei; Takahito Yoshizaki; Shinya Yamanaka; Hideyuki Okano; Norihiro Suzuki
Journal:  Hum Mol Genet       Date:  2011-09-07       Impact factor: 6.150

Review 6.  Genetic correction using engineered nucleases for gene therapy applications.

Authors:  Hongmei Lisa Li; Takao Nakano; Akitsu Hotta
Journal:  Dev Growth Differ       Date:  2013-12-11       Impact factor: 2.053

7.  Systematic evaluation of candidate ligands regulating ectodomain shedding of amyloid precursor protein.

Authors:  Heather C Rice; Tracy L Young-Pearse; Dennis J Selkoe
Journal:  Biochemistry       Date:  2013-05-02       Impact factor: 3.162

8.  Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease.

Authors:  Naoki Yahata; Masashi Asai; Shiho Kitaoka; Kazutoshi Takahashi; Isao Asaka; Hiroyuki Hioki; Takeshi Kaneko; Kei Maruyama; Takaomi C Saido; Tatsutoshi Nakahata; Takashi Asada; Shinya Yamanaka; Nobuhisa Iwata; Haruhisa Inoue
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

9.  Direct conversion of fibroblasts into functional astrocytes by defined transcription factors.

Authors:  Massimiliano Caiazzo; Serena Giannelli; Pierluigi Valente; Gabriele Lignani; Annamaria Carissimo; Alessandro Sessa; Gaia Colasante; Rosa Bartolomeo; Luca Massimino; Stefano Ferroni; Carmine Settembre; Fabio Benfenati; Vania Broccoli
Journal:  Stem Cell Reports       Date:  2014-12-31       Impact factor: 7.765

10.  Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells.

Authors:  Mason A Israel; Shauna H Yuan; Cedric Bardy; Sol M Reyna; Yangling Mu; Cheryl Herrera; Michael P Hefferan; Sebastiaan Van Gorp; Kristopher L Nazor; Francesca S Boscolo; Christian T Carson; Louise C Laurent; Martin Marsala; Fred H Gage; Anne M Remes; Edward H Koo; Lawrence S B Goldstein
Journal:  Nature       Date:  2012-01-25       Impact factor: 49.962

View more
  14 in total

Review 1.  Stepping back to move forward: a current review of iPSCs in the fight against Alzheimer's disease.

Authors:  Aditya Devineni; Scarlett Tohme; Michael T Kody; R Adams Cowley; Brent T Harris
Journal:  Am J Stem Cells       Date:  2016-10-20

2.  A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants.

Authors:  Katie J Ryan; Charles C White; Kruti Patel; Jishu Xu; Marta Olah; Joseph M Replogle; Michael Frangieh; Maria Cimpean; Phoebe Winn; Allison McHenry; Belinda J Kaskow; Gail Chan; Nicole Cuerdon; David A Bennett; Justin D Boyd; Jaime Imitola; Wassim Elyaman; Philip L De Jager; Elizabeth M Bradshaw
Journal:  Sci Transl Med       Date:  2017-12-20       Impact factor: 17.956

Review 3.  Cell models for Down syndrome-Alzheimer's disease research.

Authors:  Yixing Wu; Nicole R West; Anita Bhattacharyya; Frances K Wiseman
Journal:  Neuronal Signal       Date:  2022-04-08

Review 4.  The epigenome in Alzheimer's disease: current state and approaches for a new path to gene discovery and understanding disease mechanism.

Authors:  Hans-Ulrich Klein; David A Bennett; Philip L De Jager
Journal:  Acta Neuropathol       Date:  2016-08-29       Impact factor: 17.088

Review 5.  Stem Cells, Genome Editing, and the Path to Translational Medicine.

Authors:  Frank Soldner; Rudolf Jaenisch
Journal:  Cell       Date:  2018-10-18       Impact factor: 41.582

6.  Candidate-based screening via gene modulation in human neurons and astrocytes implicates FERMT2 in Aβ and TAU proteostasis.

Authors:  Sarah E Sullivan; Meichen Liao; Robert V Smith; Charles White; Valentina N Lagomarsino; Jishu Xu; Mariko Taga; David A Bennett; Philip L De Jager; Tracy L Young-Pearse
Journal:  Hum Mol Genet       Date:  2019-03-01       Impact factor: 6.150

Review 7.  Important advances in Alzheimer's disease from the use of induced pluripotent stem cells.

Authors:  Fernanda Majolo; Daniel Rodrigo Marinowic; Denise Cantarelli Machado; Jaderson Costa Da Costa
Journal:  J Biomed Sci       Date:  2019-02-06       Impact factor: 8.410

Review 8.  Oxidative DNA Damage Signalling in Neural Stem Cells in Alzheimer's Disease.

Authors:  Marcelina Kieroń; Cezary Żekanowski; Anna Falk; Michalina Wężyk
Journal:  Oxid Med Cell Longev       Date:  2019-11-13       Impact factor: 6.543

Review 9.  Reactive astrocytes as treatment targets in Alzheimer's disease-Systematic review of studies using the APPswePS1dE9 mouse model.

Authors:  Tamar Smit; Natasja A C Deshayes; David R Borchelt; Willem Kamphuis; Jinte Middeldorp; Elly M Hol
Journal:  Glia       Date:  2021-02-25       Impact factor: 7.452

Review 10.  APP mouse models for Alzheimer's disease preclinical studies.

Authors:  Hiroki Sasaguri; Per Nilsson; Shoko Hashimoto; Kenichi Nagata; Takashi Saito; Bart De Strooper; John Hardy; Robert Vassar; Bengt Winblad; Takaomi C Saido
Journal:  EMBO J       Date:  2017-08-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.